FDA approves morning-sickness drug withdrawn in 1980s safety scare

The FDA has resurrected a morning-sickness treatment that went not-so-gently into the good night 30 years ago, on unfounded worries about birth defects. Diclegis, a tablet made by Canadian-based Duchesnay, is a new version of Bendectin, withdrawn in 1983 because its maker couldn't afford to fight lawsuits over its safety. Release | Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.